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OBJECTIVES We hypothesized that early recurrent myocardial infarction (MI) following fibrinolytic
administration would be assessed with higher mortality at both 30 days and 2 years.
BACKGROUND Although early recurrent MI after fibrinolytic therapy has been associated with increased early
mortality in the acute MI setting, its relation to long-term mortality has not been fully
explored.
METHODS Mortality data were ascertained in 20,101 patients enrolled in the Thrombolysis In
Myocardial Infarction (TIMI) 4, 9, and 10B and Intravenous NPA for the Treatment of
Infarcting Myocardium Early (InTIME-II) acute MI trials.
RESULTS The frequency of symptomatic recurrent MI during the index hospitalization was 4.2%
(836/20,101). Recurrent MI during the index hospital period was associated with increased
30-day mortality (16.4% [137/836] vs. 6.2% [1,188/19,260], p  0.001). Likewise, recurrent
MI was associated with a sustained increase in mortality up to two years, even after
adjustments were made for covariates known to be associated with mortality and recurrent MI
(hazard ratio 2.11, p  0.001). However, this higher mortality at 2 years was due to an early
divergence in mortality by 30 days and was not due to a significant increase in late mortality
between 30 days and 2 years (4.38% [31/707] vs. 3.76% [685/18,206], pNS). Percutaneous
coronary intervention during the index hospitalization was associated with a lower rate of
in-hospital recurrent MI (1.6% vs. 4.5%, p  0.001) and lower two-year mortality (5.6% vs.
11.6%, p  0.001). Performance of coronary artery bypass graft surgery was also associated
with a lower recurrent rate of MI (0.7% vs. 4.3%, p  0.001) and lower two-year mortality
rate (7.95% vs. 10.6%, p  0.0008).
CONCLUSIONS Early recurrent MI is associated with increased mortality up to two years. However, most
deaths occur early, and the risk of additional deaths between the index hospital period and
two years was not significantly increased among patients with recurrent MI. Percutaneous
coronary intervention during the index hospitalization was associated with a lower risk of
recurrent MI and a lower risk of two-year mortality. (J Am Coll Cardiol 2003;42:7–16)
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The incidence of symptomatic recurrent myocardial infarc-
tion (MI) has been reported to be between 2% and 6% by
four to six weeks after fibrinolytic administration (1–6).
See page 17
Death from recurrent MI remains a limitation of fibrinolytic
therapy (1–7). Because recurrent MI is associated with the
primary end point of mortality, many recent fibrinolytic
trials have adapted death or recurrent MI as a key secondary
end point (7). Although recurrent MI has been associated
with short-term mortality (7), its relation to long-term
mortality in the era of newer fibrinolytic, antithrombotic,
and antiplatelet agents, as well as new device technologies,
is less well characterized.
Because recurrent MI may be associated with more severe
left ventricular dysfunction, we hypothesized that recurrent
MI before discharge from the index hospitalization would
not only be associated with higher mortality by 30 days but
also later, up to 2 years. Furthermore, we hypothesized that
early recurrent MI would be associated with an additional
increase in late mortality, between 30 days and 2 years.
Finally, we hypothesized that performance of a percutane-
ous coronary intervention (PCI) during the index hospital
period would be associated with a lower subsequent risk
of recurrent MI and death. The data of over 20,000
patients enrolled in the Thrombolysis In Myocardial Infarc-
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tion (TIMI) 4, 9, and 10B and Intravenous NPA for the
Treatment of Infarcting Myocardium Early (InTIME-II, or
TIMI 17) trials were analyzed to test these hypotheses.
METHODS
Patient population. Both 30-day and long-term mortality
data (up to 2 years) from the TIMI 4, 9, and 10B and
InTIME-II acute MI trials were analyzed (n  20,101).
The TIMI 4 trial was a randomized, double-blinded com-
parison of three fibrinolytic regimens: anistreplase (emi-
nase), front-loaded recombinant tissue-type plasminogen
activator (rt-PA) (activase or alteplase), and combination
therapy in 416 patients (8). Both TIMI 9A (n  757) and
TIMI 9B (n  3,002) were multicenter, randomized trials
evaluating the safety and efficacy of hirudin as an adjunct to
fibrinolytic therapy (rt-PA or streptokinase at the physi-
cian’s discretion) (9,10). The TIMI 10B study was an
880-patient, randomized trial comparing 30, 40, and 50 mg
of tenecteplase, a mutant of rt-PA, with front-loaded
alteplase (11). The TIMI 17 (InTIME-II) study was an
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CI  confidence interval
CK  creatine kinase
HR  hazard ratio
InTIME-II  Intravenous NPA for the Treatment of
Infarcting Myocardium Early trial
IQR  interquartile range
MI  myocardial infarction
PCI  percutaneous coronary intervention
rt-PA  recombinant tissue-type plasminogen
activator
TIMI  Thrombolysis In Myocardial Infarction
trial
TRS  Thrombolysis In Myocardial Infarction
risk score
ULN  upper limit of normal
Table 1. Baseline Characteristics
Variable
Recurrent MI
(n  836)
No Recurrent MI
(n  19,265) p Value
Age (yrs) 63.4  11.6 60.7  12.0  0.001
Male gender (%) 71.4 75.3 0.012
White (%) 92.8 92.1 0.435
Hypertension (%) 37.5 31.6  0.001
Diabetes (%) 14.5 14.3 0.872
Angina (%) 31.0 23.5  0.001
CHF* (%) 3.5 2.9 0.390
Current smoker (%) 35.8 45.3  0.001
Previous MI (%) 22.4 15.9  0.001
Anterior infarct location (%) 43.5 41.8 0.314
Heart rate (beats/min) 73.9  16.8 75.9  17.7 0.002
Blood pressure (mm Hg)
Systolic 136.2  21.3 136.8  21.9 0.444
Diastolic 80.8  13.7 81.1  13.8 0.573
Weight (kg) 77.3  15.2 78.4  14.8 0.042
Symptom onset to treatment (h) 2.5 (1.8–3.75) 2.85 (2–4)  0.001†
Pre-admission medication (%)
Aspirin 29.0 20.3  0.001
Beta-blocker 23.1 14.7  0.001
Calcium channel blocker 22.6 15.7  0.001
Nitrate 24.6 18.7  0.001
ACE inhibitor 12.8 11.7 0.334
*History of CHF not collected in TIMI 4. †Wilcoxon rank-sum. Data are presented as the mean value  SD, percentage of
subjects, or median value (interquartile range).
ACE  angiotensin-converting enzyme; CHF  congestive heart failure; MI  myocardial infarction.
Table 2. Incidence of Recurrent MI by In-Hospital
Medication Use
Medication
Recurrent MI
(n  836) p Value
Fibrinolytic (%) 0.010
tPA 4.5
SK 3.3
TNK 3.9
nPA 3.9
APSAC 8.8
APSAC  tPA 4.6
Beta-blocker (%) 0.792
Yes 4.1
No 4.2
Calcium channel blocker (%)  0.001
Yes 6.8
No 3.8
Nitrate (%)  0.001
Yes 4.6
No 2.6
ACE inhibitor (%) 0.001
Yes 4.6
No 3.7
APSAC  anisoylated plasminogen streptokinase activator complex; nPA  lanote-
plase; SK  streptokinase; tPA  tissue-type plasminogen activator; TNK 
tenecteplase; other abbreviations as in Table 1.
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noninferiority trial (n 15,078) that compared single-bolus
intravenous lanoteplase with front-loaded alteplase (12).
End points and definitions. Recurrent MI was adjudi-
cated by a Clinical Events Committee in TIMI 4, TIMI 9,
and InTIME-II and was prospectively assessed by the local
investigators in TIMI 10B. In all trials, reinfarction within
18 h of the index MI was defined as recurrent chest pain
lasting at least 30 min, associated with new or recurrent
Figure 1. (A) Kaplan-Meier curves relating short-term and long-term outcomes to recurrent myocardial infarction (MI). Most deaths among patients with
early reinfarction occurred early, and the curves did not shift between 30 days and 2 years of follow-up. (B) Kaplan-Meier estimated mortality rates up to two years
by in-hospital reinfarction, stratified by Thrombolysis In Myocardial Infarction risk score (TRS). Mortality was higher in patients with reinfarction in the low,
intermediate, and high TRS groups. In the analysis adjusting for age, gender, anterior MI, pulse rate on admission, history of hypertension, previous angina, current
smoker, previous MI, weight, and time from symptom onset to treatment, the p value was 0.001 in each of the TRS groups.
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ST-segment elevation 0.1 mV in at least two contiguous
electrocardiographic leads. After 18 h of fibrinolytic admin-
istration, there had to be enzyme or electrocardiographic
evidence of MI in addition to recurrent chest pain. In TIMI
4, 9, and 10B, the requirement was creatine kinase-MB
fraction (CK-MB) greater than the upper limit of normal
(ULN). In TIMI 9 and 10B, the value also had to be50%
increased over the previous value. In TIMI 9 and 10B, after
coronary angioplasty, the definition of recurrent MI was
new Q waves in two or more leads and re-elevation of
CK-MB (or total CK if CK-MB was not available) to at
least twice the ULN and 50% above the previous value;
after coronary artery bypass graft surgery (CABG), the latter
criterion was set at CK-MB elevation to at least five times
the ULN with new Q waves. In InTIME-II, two of the
following conditions were required for reinfarction: chest
pain lasting 20 min not relieved by nitroglycerin, new
ST-segment elevation 0.1 mV or new abnormal Q waves,
and serum CK 2 times the ULN and 50% above the
lowest CK level from the index MI.
Performance of PCI and CABG was assessed through
index hospitalization discharge in all trials. Use of PCI or
CABG was left to the discretion of the investigator and was
not protocol-mandated. Patients who experienced recurrent
MI before their delayed PCI (n  288) or CABG (n  76)
were analyzed as medically treated patients, because their
recurrent MI presumably led to the intervention. Patients
with PCI or CABG and recurrent MI on the same day but
with a missing time of MI (n  11) or revascularization (n
 45) were excluded from the revascularization analysis, as
the sequence of the events (whether the MI preceded or
followed revascularization) could not be ascertained. Recurrent
MIs that developed after revascularization were counted
among the MIs that occurred in the revascularization strategy.
The distribution of the TIMI risk score (TRS) for
ST-segment elevation acute MI, as previously reported, was
used to assess the effect of recurrent MI and revasculariza-
tion on mortality in low-risk (TRS 0 to 2), intermediate-
risk (TRS 3 and 4), and high-risk (TRS 5 to 7) patients
(13). The TRS was developed to identify the patients’ risk
of 30-day mortality.
Statistical analysis. All analyses were performed using
Stata Statistical Software (version 7.0, Stata Corp., College
Station, Texas). All continuous variables are reported as the
mean value  SD. The Student t test or analysis of variance
was utilized for the analysis of continuous variables. The
nonparametric Wilcoxon rank-sum test was used when the
data were not normally distributed, according to the skew-
ness/kurtosis tests for normality by D’Agostino et al. (14).
The chi-square test was used for the analysis of categorical
variables. Kaplan-Meier curves were generated, and the
log-rank test was used to test the equality of the survivor
function across groups. The Cox proportional hazards
model was used to estimate maximum-likelihood propor-
tional hazard ratios.
RESULTS
Patient characteristics. The median duration of follow-up
was 456 days (interquartile range [IQR]: 361 to 580 days).
Figure 2. Kaplan-Meier curves relating long-term outcomes (up to two years) to recurrent myocardial infarction in patients who were alive at hospital
discharge. There was no difference in mortality in patients with an early reinfarction when the analysis was restricted to patients who survived the index
hospitalization (p  0.45 by log-rank).
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Of the 20,105 patients enrolled in the five trials, 4 patients
did not have follow-up through 30 days. At 6 months,
follow-up was available in 16,180 patients. A total of 5,122
patients had follow-up for 1 year. For the majority of
patients (n 14,379), follow-up occurred for between 1 and
2 years, and 598 patients had 2 years of follow-up. All
data after two years were censored at two years.
Recurrent MI during the hospitalization for the index
MI occurred in 836 (4.2%) of the 20,101 patients at a
median of 2.2 days (IQR 0.2 to 4.7). Patients who sustained
Figure 3. (A) Kaplan-Meier curves relating short-term and long-term outcomes (up to two years) to percutaneous coronary intervention (PCI) use during
the index hospitalization. In the analysis adjusting for age, gender, anterior myocardial infarction (MI), pulse rate on admission, history of hypertension,
previous angina, current smoker, previous MI, weight, and time from symptom onset to treatment, the p value was 0.001. (B) Kaplan-Meier estimated
mortality rates up to two years by in-hospital PCI, stratified by Thrombolysis In Myocardial Infarction risk score (TRS). Mortality was lower in patients
who underwent PCI in the low, intermediate, and high TRS groups. In the analysis adjusting for age, gender, anterior MI, pulse rate on admission, history
of hypertension, previous angina, current smoker, previous MI, weight, and time from symptom onset to treatment, the p value was 0.001 in each of the
TRS groups.
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a recurrent MI were more likely to have had a previous
MI and a history of hypertension and were older and
more likely to be female (Table 1). There were differ-
ences in the frequency of recurrent MI in patients
who received a calcium channel blocker, nitrate, and
angiotensin-converting enzyme inhibitor during the index
hospitalization (Table 2).
Reinfarction and mortality. The frequency of symptom-
atic recurrent MI during the index hospitalization was 4.2%
(836/20,101). Among patients who sustained a recurrent
MI during the index hospitalization, 30-day mortality was
increased (16.4% [137/836] vs. 6.2% [1,188/19,260], p 
0.001). This association persisted after adjustment for co-
variates known to be associated with 30-day mortality and
covariates associated with recurrent MI (p  0.05 on
univariate analysis) (Table 1), including age, gender, ante-
rior MI, pulse rate on admission, history of hypertension,
previous angina, current smoker, previous MI, weight, and
time from symptom onset to treatment (hazard ratio [HR]
2.55, 95% confidence interval [CI] 2.12 to 3.06; p 0.001).
Mortality remained higher during follow-up among pa-
tients with recurrent MI, as compared with those without
recurrent MI, even after adjustment for age, gender, anterior
MI, pulse rate on admission, history of hypertension,
previous angina, current smoker, previous MI, weight,
and time from symptom onset to treatment (HR 2.11, 95%
CI 1.79 to 2.50; p  0.001) (Fig. 1A). The unadjusted
six-month mortality rates for the two groups by reinfarction
status were 18.5% (re-MI) and 8.0% (no re-MI). The
corresponding mortality rates at 12, 18, and 24 months were
19.3% vs. 9.0%, 19.6% vs. 9.6%, and 19.6% vs. 10.1%,
respectively. Similar results were seen across the low, inter-
mediate, and high TRS categories (Fig. 1B).
In an analysis restricted to patients who survived the
index hospitalization, long-term mortality up to two years
was not significantly higher in patients who had a reinfarc-
tion during the index hospital period (p 0.45 by log-rank)
(Fig. 2). The unadjusted two-year mortality rates in this
analysis were 4.9% (re-MI) and 4.9% (no re-MI) (p  NS).
At one year, these values were 4.5% (re-MI) and 3.7% (no
re-MI) (p  NS).
Mortality and in-hospital reinfarction by performance of
revascularization. Percutaneous coronary intervention was
performed in 4,281 (21.4%) of 20,043 patients during the
index hospitalization at a median of four days after fibrino-
lytic administration (IQR 1 to 8). Reinfarction occurred less
frequently among patients treated with PCI (1.6% vs. 4.5%,
p  0.001). Similar results were seen across the low,
intermediate, and high TRS categories (p 0.001 for each).
In patients treated with PCI, mortality was lower during the
index hospitalization (2.76% vs. 6.75%, p  0.001), at 30
days (2.97% vs. 7.56%, p 0.001), and up to 2 years (5.62%
vs. 11.59%, p  0.001) (Fig. 3A). Similar results were seen
across the low, intermediate, and high TRS categories (Fig.
3B). Mortality was highest among patients with recurrent
MI who were not treated with PCI (in-hospital mortality
rate of 23.6%) and lowest (2.6%) among patients without
recurrent MI who were treated with PCI (Table 3). Both
PCI and recurrent MI remained associated with mortality in
a model adjusting for age, gender, anterior MI, pulse rate on
admission, history of hypertension, previous angina, current
smoker, previous MI, weight, and time from symptom onset
to treatment (PCI-related HR 0.52, 95% CI 0.44 to 0.61, p
 0.001; recurrent MI-related HR 1.98, 95% CI 1.66 to
2.36, p  0.001).
Coronary artery bypass graft surgery was performed in
1,048 (5.2%) of 20,092 patients during the index hospital-
ization at a median of eight days after fibrinolytic adminis-
tration (IQR 4 to 13). Reinfarction occurred less frequently
among patients treated with CABG (0.7% vs. 4.3%, p 
0.001), and mortality was lower (p  0.0008) (Fig. 4A).
When stratified by TRS, mortality was lower in CABG-
treated patients in the high-risk group (p  0.0021), with a
trend toward being lower in the intermediate-risk group (p
 0.0933), but showed no difference in the low-risk group
(p  0.7845) (Fig. 4B). Both CABG and recurrent MI
remained associated with mortality in a model adjusting for
age, gender, anterior MI, pulse rate on admission, history of
hypertension, previous angina, current smoker, previous
MI, weight, and time from symptom onset to treatment
(CABG-related HR 0.63, 95% CI 0.48 to 0.81, p  0.001;
recurrent MI-related HR 2.06, 95% CI 1.75 to 2.44, p 
0.001).
Use of any revascularization (PCI or CABG) occurred in
5,238 (26.1%) of 20,039 patients during the index hospi-
talization at a median of five days after fibrinolytic admin-
istration (IQR 2 to 9). Reinfarction occurred less frequently
among patients treated with revascularization (1.4% vs.
Table 3. Mortality by In-Hospital Reinfarction and Use of PCI
Recurrent MI Absent
Recurrent MI Present
p Value
(5-way)
No PCI
(n  15,051)
PCI
(n  4,212)
Treated
With PCI
(n  288)
Not Treated
With PCI
(n  423)
PCI Complicated by
Reinfarction After PCI
(n  69)
In-hospital mortality 6.31% 2.61% 5.21% 23.64% 11.59%  0.001
30-day mortality 7.10% 2.83% 5.56% 25.06% 11.59%  0.001
2-year mortality* 10.38% 4.25% 6.60% 29.55% 11.59%  0.001
2-year mortality† 11.15% 5.52% 7.23% 29.88% 11.59%  0.001
*Raw percentages. †Kaplan-Meier estimates.
MI  myocardial infarction; PCI  percutaneous coronary intervention.
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4.7%, p  0.001), and mortality was lower (p  0.0001)
(Fig. 5A). Similar results were seen across the low, inter-
mediate, and high TRS categories (Fig. 5B). Both revascu-
larization and recurrent MI remained associated with mor-
tality in a model adjusting for age, gender, anterior MI,
pulse rate on admission, history of hypertension, previous
angina, current smoker, previous MI, weight, and time from
symptom onset to treatment (revascularization-related HR
0.51, 95% CI 0.44 to 0.59, p  0.001; recurrent MI-related
HR 1.92, 95% CI 1.61 to 2.30, p  0.001).
DISCUSSION
This analysis demonstrates that in-hospital recurrent MI
following fibrinolytic administration is associated with an
increased risk of long-term mortality up to two years, but
this risk appears to be attributable primarily to an increase in
early mortality during the index hospitalization. After ad-
justment for other known correlates of mortality, reinfarc-
tion remained significantly associated with long-term mor-
tality for up to two years after the index MI. However,
Figure 4. (A) Kaplan-Meier curves relating short- and long-term outcomes (up to two years) to coronary artery bypass graft surgery (CABG) use during
the index hospitalization. (B) Kaplan-Meier estimated mortality rates up to two years by in-hospital CABG, stratified by Thrombolysis In Myocardial
Infarction risk score (TRS). Mortality was lower in patients who underwent CABG in the high TRS groups, with a trend toward being lower in the
intermediate-risk group, but showed no difference in the low-risk score group.
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long-term mortality up to two years among patients who
survived the index hospital period was not significantly
increased among patients with versus without reinfarction.
Our findings complement and expand on previous studies
that have associated increased long-term mortality with
in-hospital reinfarction (4–7,15,16). The 4.2% incidence of
reinfarction in this cohort of patients is similar to the 2.1%
to 6.1% incidence reported in other large fibrinolytic trials
(1,2,17,18). An analysis of the TIMI II trial demonstrated
an increased relative risk (RR) of death at three-year
follow-up in patients with early reinfarction following fibri-
nolysis, as compared with patients without reinfarction (RR
1.9, 99% CI 1.1 to 3.2) (19). Pooled results from the Global
Utilization of Streptokinase and tPA (alteplase) for Oc-
cluded arteries (GUSTO I) and Global Use of Strategies To
Open occluded arteries (GUSTO III) trials showed a
similar trend toward late mortality among patients with
nonfatal reinfarction compared with those without reinfarc-
tion (adjusted HR 1.25, 95% CI 0.97 to 1.61) (7).
One potential strategy to reduce the risk of recurrent MI
after fibrinolytic administration, as suggested by our data,
might be the performance of revascularization during the
Figure 5. (A) Kaplan-Meier curves relating short- and long-term outcomes (up to two years) to revascularization (percutaneous coronary intervention [PCI]
or coronary artery bypass graft surgery [CABG]) use during the index hospitalization. (B) Kaplan-Meier estimated mortality rates up to two years by
in-hospital revascularization (PCI or CABG), stratified by Thrombolysis In Myocardial Infarction risk score (TRS). Mortality was lower in patients who
underwent revascularization in the low, intermediate, and high TRS groups.
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index hospitalization. Although early randomized trials
failed to demonstrate a benefit in the performance of
conventional angioplasty soon after fibrinolytic administra-
tion, these trials preceded the use of stents, thienopyridines,
platelet glycoprotein IIb/IIIa inhibitors, and the monitoring
of activated clotting times (20–22). More recent observa-
tional studies that incorporate these current practices have
demonstrated the safety and potential efficacy of performing
PCI after fibrinolytic administration (23–25).
In the present study, performance of revascularization
during the index hospital period was associated with a lower
rate of in-hospital recurrent MI and lower rates of early and
long-term mortality up to two years. This association was
observed in multivariate models adjusting for potential
confounders and was also observed among patients at
varying risk, as assessed using TRS. The timing of recurrent
MI and performance of revascularization were carefully
evaluated to ensure that the events were assigned to the
appropriate strategy.
These retrospective observational findings are consistent
with the hypothesis that performance of PCI after fibrino-
lytic administration during the index hospitalization is
associated with a reduced risk of in-hospital recurrent MI,
and a reduction in the risk of recurrent MI may, in turn,
confer a favorable long-term prognosis. Prospective, ran-
domized studies are warranted to validate this finding.
Study limitations. Several limitations of this study should
be considered. This is a retrospective, observational analysis
based on several trials. Although we controlled for variables
previously identified as associated with mortality and recur-
rent MI (e.g., age, gender, anterior MI, pulse rate on
admission, history of hypertension, previous angina, current
smoker, previous MI, weight, time from symptom onset to
treatment), unidentified confounders may have contributed
to these findings. Recurrent MI was adjudicated in 19,255
(95.8%) of the 20,101 patients. Multiple definitions were
used for recurrent MI. Data were unavailable as to which
definition was used for each specific case of recurrent MI.
As such, it is undetermined whether each definition of MI
had the same effect on mortality and whether PCI affected
the types of reinfarction and subsequent mortality.
Conclusions. Recurrent MI after fibrinolytic administra-
tion during the index hospitalization is associated with
increased mortality up to two years. However, most of these
deaths occur early, and the risk of additional deaths between
the index hospitalization and two years did not appear to be
increased. Performance of adjunctive PCI or CABG is
associated with a lower rate of recurrent MI and death.
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